Fundraising Fox
Longitude Capital
Growth equityMenlo Park · Series A–Late Stage · 72 people tracked
Also known as LONGITUDE CAPITAL MANAGEMENT CO., LLC · Longitude Venture Partners
Find your way into Longitude Capital
Each arrow is one introduction. Sign up to fill in the first one.
Ask Dennis Gong to introduce you to Ms. Helms
You →Dennis · together at Longitude Capital →Ms.
Ask Jamie Chen to introduce you to Patrick Enright
You →Jamie · together at Longitude Capital →Patrick
Ask Sam Okafor to introduce you to Marc Galletti
You →Sam · together at Amerindo Investment Advisors →Marc
- Ms. Bakker57 people can intro you
- Mr. Bikoff26 people can intro you
- Mr. Enright26 people can intro you
Sign up to find every way you can get introduced to Longitude Capital
- Your email: who you already know at Longitude Capital, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Longitude Capital team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Longitude Capital pursues a venture growth strategy focused on biotechnology, medical technology, and health solutions companies working to improve clinical outcomes, enhance patient quality of life, and lower the cost of care. It builds a balanced portfolio of clinical-stage and commercial-stage companies with clinically de-risked assets, favorable valuations relative to risk, and expected returns within three to five years of initial investment. The firm invests in both private and public companies using varied structures including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, and royalties. It sources opportunities via industry relationships and proprietary thematic research, then works closely with portfolio companies and syndicate partners to execute strategic plans and pursue liquidity.
Source: firm website, verified Sep 29, 2026.
Team · 72 people
from the firm's website & curated & public directories
Founder mafia
2 people who came through Longitude Capital went on to found or lead other companies.
What they invest in
from 106 of 152 portfolio companiesBiotech ×66Healthtech ×65Medical Devices ×43Digital Health ×23AI & Machine Learning ×9Hardware ×9SaaS ×8Deep Tech ×5
HQs:United States×81Canada×1Switzerland×1Ireland×1Netherlands×1
Who they back
founder profiles across 54 portfolio companiesFounding team size:solo founder×322 founders×143 founders×54+ founders×3
Where their founders studiedfrom 36 founders with education data
Harvard Medical School ×5Harvard University ×2UC Santa Barbara ×2University of New Hampshire ×2University of Wisconsin-Madison ×2
What their founders studiedfrom 37 founders with field-of-study data
Business & Management ×10Life Sciences ×10Engineering ×7Medicine ×7Computer Science ×6Chemistry ×3Finance & Accounting ×3Economics ×2
Where their founders worked beforefrom 39 founders with career history
AnaptysBio ×2Axonius ×2Harvard Medical School ×2Johnson & Johnson ×2Kleiner Perkins ×2
13 founders hold a PhD · 10 hold an MBA (of 41 with degree data)
Investments · 152 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 22024 · 72023 · 22022 · 42021 · 52020 · 42019 · 32018 · 82017 · 62015 · 32014 · 451 dated
Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.
BiotechHealthtechWest Hartford, US
Reid Waldman(Chief Executive Officer and Board Member)inTim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)
Co-investorsConnecticut InnovationsLifeSci Venture PartnersOUP (Osage University Partners)SR One Capital Managementabrdn plcInvus
Ceribell is a medical technology company that develops products for detecting and monitoring seizures, including EEG-based diagnostic systems.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSunnyvale, US
Josef Parvizi(Director)inXingjuan (Jane) Chao(President, CEO, Co-Founder & Director)inScott Blumberg(Executive Officer)inJoseph Taylor(Director)Raymond Woo(Executive Officer)David Stoffel(Executive Officer)
Board seatJuliet Tammenoms Bakker· per SEC Form D
Co-investorsRA CapitalRed Tree VentureShangBay Capital LLCThe Rise Fund
AEON Biopharma develops botulinum toxin biosimilars and therapeutic neurotoxin treatments for patients with neuromuscular disorders.
BiotechHealthtechMedical Devices
Robert Bancroft(President, Chief Executive Officer and Director)John Bencich(Chief Financial Officer)inChad Oh(Chief Medical Officer)inAlex Wilson(Chief Legal & Strategy Officer; Corporate Secretary)inJennifer Sy(Chief Accounting Officer)in
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Founder)inEric Morgen(Founder)inDov Goldstein(Executive Officer)in
BoardPatrick Enright(Director)in
Co-investorsAndreessen HorowitzElad GilFelicis VenturesGreen Sands EquityIA Seed VenturesOrbiMed+20 more
Boston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
HealthtechMedical Devices
John Abele(Founder)inPeter Nicholas(Founder)Lance BatesinJonathan R. Monson(Executive Vice President and Chief Financial Officer)Miriam O'Sullivan(Senior Vice President, Chief Human Resources Officer)inMichael F. Mahoney(Chairman of the Board, President and Chief Executive Officer)
Co-investorsAndera PartnersCatalyst Health VenturesCouncilExcelestar VenturesGood Growth CapitalKleiner Perkins+8 more
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Arthur Kuan(Chairman and Chief Executive Officer)in
Co-investorsDecheng CapitalForesite CapitalPalm Drive CapitalRA CapitalTCG CrossoverACORN BIOVENTURES+3 more
Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions.
BiotechCanton, US
Michael Heffernan(Executive Officer, Director)inPaul Brannelly(Executive Officer)inVikram Karnani(President and Chief Executive Officer, and Director)in
BoardEran Nadav(Director)John Freund(Director)Patrick Heron(Director)in
Co-investorsAPERTURE Venture PartnersEcoR1 CapitalFrazier Life SciencesBoston Millennia PartnersRA Capital
Corcept develops cortisol modulators — molecules that regulate cortisol activity at the glucocorticoid receptor — to treat serious diseases across endocrinology, oncology, metabolism, and neurology.
AI & Machine LearningBiotechHealthtechMedical Devices
Joseph K. Belanoff(Chief Executive Officer and President)
Co-investorsMountain Group CapitalRidgeback Capital
CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.
BiotechHealthtechSouth San Francisco, US
Sean A. McCarthy(Chief Executive Officer and Chairman)inMarcia P. Belvin(SVP, Chief Scientific Officer)inDawn Benson(SVP, Quality and Product Manufacturing)inWayne Chu(Chief Medical Officer)Rachael Lester(SVP, Chief Business Officer)inChris Ogden(Chief Financial Officer)in
Co-investorsATEL VenturesCanaan PartnersPfizer Venture InvestmentsWellington ManagementOrbiMedThird Rock Ventures
A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.
BiotechArlington, US
Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)inTodd Bazemore(Executive Officer)inMark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in
Co-investorsSR One Capital ManagementWellington ManagementYsios CapitalAtlas VentureLux CapitalRA Capital+1 more
Kestra Medical Technologies develops wearable medical devices and digital healthcare solutions designed for collaborative care between providers and patients.
Digital HealthHardwareHealthtechMedical Devices
Brian Webster(President, Chief Executive Officer, and Director)inTraci S. Umberger(General Counsel, Chief Administrative Officer, and Director)inVaseem Mahboob(Chief Financial Officer)inAl Ford(Chief Commercial Officer)inTimothy Moran(Chief Business Officer)
Co-investorsAndera PartnersBain Capital Life SciencesStar51 CapitalBain Capital
Mobia Medical (formerly MicroTransponder) develops Vivistim Paired VNS Therapy, an FDA-approved treatment for stroke survivors with moderate to severe upper extremity impairment.
Digital HealthHealthtechMedical DevicesAustin, US
Richard John Foust(Executive Officer, Director)Frank McEachern(Executive Officer, Director)in
BoardNelson Bunker Curnes(Executive Officer, Director)Thomas Jordan Curnes II(Executive Officer, Director)Casey Tansey(Director)Dana Mead(Director)
Co-investorsUT Horizon FundGreen Park & Golf VenturesUS Venture Partners
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardPatrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)
Co-investorsChiesi VenturesFrazier Life SciencesMESA VERDE VENTURE PARTNERSNew Enterprise Associates (NEA)Pappas CapitalRiverVest Venture Partners+4 more
PROCEPT BioRobotics develops robotic-assisted surgical technology for men's health, focused on treating benign prostatic hyperplasia (BPH).
HealthtechMedical DevicesRoboticsRedwood City, US
Nikolai Aljuri, Ph.D.(Executive Officer, Director)Larry L. Wood(President, Chief Executive Officer & Director)Kevin Waters(EVP, Chief Financial Officer)inAlaleh Nouri(EVP, Chief Legal Officer & Corporate Secretary)in
BoardFred Moll(Director)inColby Wood(Director)
Co-investorsSonder CapitalViking GlobalSonder Futures
Rapid Micro Biosystems manufactures automated laboratory testing systems and consumables for pharmaceutical and cell therapy manufacturers to conduct microbiological quality control testing, replacing manual methods with platform-based analysis.
HealthtechLowell, US
Robert Spignesi(Executive Officer, Director)inStephen H. Delity(Executive Officer, Director)Michael J. Mullen(Executive Officer)
BoardDavid Hirsch(Director)Richard S. Kollender(Director)Fred Cohen(Director)
Co-investorsEndeavour VisionKleiner PerkinsXeraya CapitalAlly Bridge Group
RxSight develops the Light Adjustable Lens (LAL), an FDA-approved intraocular lens that surgeons can adjust after cataract surgery to fine-tune a patient's prescription once the eye has healed.
HealthtechMedical DevicesPasadena, US
Robert H. Grubbs(Director)Daniel M. Schwartz(Director)D. Verne Sharma(Executive Officer, Director)Richard Drinkward(Executive Officer)inRon Kurtz(President, Chief Executive Officer & Director)Mark Wilterding(Chief Financial Officer)in
Co-investorsFlying L PartnersForesite CapitalH.I.G. CapitalH.I.G. HealthBridge PartnersRA CapitalVisionary Ventures+2 more
Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases.
BiotechDeep TechHealthtechSouth San Francisco, US
Grant Pickering(Chief Executive Officer, Director and Co-Founder)Jeff Fairman(Vice President of Research and Co-Founder)Ashish Khanna(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in
Co-investorsAbingworthCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesJanus Henderson InvestorsMedicxi+4 more
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
BiotechHealthtech
Grant Pickering(Founder)in
Co-investorsBioRock VenturesCTI Life Sciences Fund L.P.Foresite CapitalFrazier Life SciencesPivotal Life SciencesRA Capital+3 more
Vera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant.
BiotechDigital HealthMedical DevicesSouth San Francisco, US
Marshall Fordyce(Executive Officer, Director)in
BoardBeth Seidenberg(Director)inMaha Katabi(Director)inKurt von Emster(Director)inPatrick Enright(Director)inAndrew Cheng(Director)
Co-investorsKleiner PerkinsSofinnova VenturesAbingworthSofinnova Venture Partners
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Co-investorsDelos CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersPivotal Life SciencesQuan CapitalSR One Capital Management+3 more
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalBioMedPartnersFrazier Life SciencesJeito CapitalNovo HoldingsOrbiMed+5 more
Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Michael Tolentino(Executive Officer, Director)inMohamed A. Genead(Chairman & CEO)inDavid Callanan(Executive Officer)inDerek Kunimoto(Executive Officer)inJeffrey Nau(Chief Executive Officer)inTarek S. Hassan(Chief Development Officer)in
Co-investorsJeito CapitalCatalio Capital Management, LPOrbiMedAvoro Capital AdvisorsDigitalis VenturesOmega Funds
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.
BiotechHealthtechSan Carlos, US
Anthony Ford(Executive Officer, Director)inBenjamin Potter(Executive Officer)Henry Skinner(Director)Liam Ratcliffe(Director)in
BoardRon Hunt(Director)inLoretta Tse, Ph.D.(Director)
Co-investorsAlta Partnersabrdn plcIntermediate Capital GroupJohnson & Johnson Innovation – JJDCNew Leaf Venture PartnersPappas Capital+2 more
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.
BiotechDeep TechMedical DevicesMenlo Park, US
Mani Subramanian(Executive Officer, Director)inGangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers
BoardMatthew Young(Director)inSrinivas Akkaraju(Director)
Co-investorsAscenta CapitalSamsara BioCapitalF-Prime Capital
Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia.
BiotechDigital HealthDel Mar, US
Patrick Johnson(Executive Officer, Promoter)inMary Jaqueline Johnson(Executive Officer)Mary Jacqueline Johnson(Executive Officer)Kevin Johnson(Director)Greg Ostrow(Executive Officer, Director)Kenneth Widder(Executive Officer, Director)
Co-investorsRA CapitalVisionary Ventures
Boston Scientific develops medical devices and technologies used by healthcare professionals to treat patients across a range of conditions.
HealthtechMedical DevicesIrvine, US
Michael Williamson(Executive Officer)Dan L. Dearen(Executive Officer)inRaymond Cohen(Executive Officer, Director)in
BoardDarren Cai(Director)Raphael Wisniewski(Director)Erik Amble(Director)
Board seatMs. Bakker· per SEC Form D
Co-investorsAdvent Life SciencesAndera PartnersGilde Healthcare
Venus develops non-invasive, energy-based medical aesthetic devices for body, face, skin, and hair treatments, integrating robotics, AI, and IoT technologies.
BiotechHardwareHealthtechMedical DevicesToronto, US
Domenic Serafino(Executive Officer, Director)inKirk Gunhus(Executive Officer)inRoss Portaro(Executive Officer)inAnna Georgiadis(Executive Officer)inMelissa Kang(Executive Officer)inMichael Mandarello(Executive Officer)in
Board seatMs. Bakker· per SEC Form D
Co-investorsAPERTURE Venture PartnersEssex Woodlands Healthcare PartnersClarus VenturesHealthQuest Capital
A clinical-stage biopharmaceutical company developing investigational therapies for patients with liver and cardiometabolic diseases, with a lead candidate (pegozafermin) being evaluated for metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.
BiotechHealthtechMedical DevicesSan Francisco, US
Rohan Palekar(Founder)in
Co-investorsK2 HealthVenturesRA Capital
Aimmune Therapeutics developed desensitization treatments for life-threatening food allergies, including Palforzia, the first FDA-approved peanut allergy treatment.
Co-investorsAisling CapitalForesite CapitalMenlo Ventures
Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.
BiotechPalo Alto, US
James Li(Executive Officer, Director)Maria Fardis(Executive Officer, Director)in
BoardAnna Chen(Director)Colin Walsh(Director)Evan Caplan(Director)Jill Carroll(Director)in
Co-investorsFrazier Life SciencesOrbiMedSR One Capital Management
Akebia Therapeutics develops FDA-approved drug therapies for the treatment of kidney disease.
BiotechHealthtechMedical DevicesCambridge, US
John P. Butler(President and Chief Executive Officer)in
Co-investorsCincyTech
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture Partners+9 more
.png)
Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.
BiotechLongevityMedical Devices
Co-investorsFrazier Life SciencesWUTIF CapitalAscenta CapitalBiotechnology Value FundLightspeed Venture PartnersNextech Invest+1 more
Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease.
BiotechHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsFountain Healthcare PartnersSignet Healthcare PartnersSofinnova Ventures
Amphora provides logistics services aimed at supporting business growth and operational efficiency.
E-commerceLogistics & Supply ChainSaaS
Joan Tresserras(Founder)inAdrià Cortés(Founder)in
Co-investorsBStartupBaird CapitalF-Prime CapitalHBM Healthcare Investments
Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.
South San Francisco, US
Co-investorsBain Capital Life SciencesFrazier Life SciencesViking GlobalBlackRockCasdin CapitalFranklin Templeton+6 more
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLatterell Venture PartnersOUP (Osage University Partners)Agent CapitalBain Capital+3 more
Aptus Endosystems developed endovascular devices, including the Heli-FX EndoAnchor systems, that use helical anchors to secure stent-grafts during minimally invasive aortic aneurysm repair.
HealthtechMedia & EntertainmentMedical Devices
Co-investorsUS Venture Partners
Assembly Bio is a biopharmaceutical company developing novel therapeutic candidates for viral and liver diseases, including programs targeting herpesviruses, hepatitis delta virus, hepatitis B virus, and cholestatic liver diseases.
BiotechHealthtechMedical Devices
Jason Okazaki(Chief Executive Officer & President)inWilliam Delaney, PhD(Chief Scientific Officer)Anuj Gaggar, MD, PhD(Chief Medical Officer)
Co-investorsAvoro Capital Advisors
Biotechnology company developing the LOCOcyte cell-therapy platform for local dosing of immunotherapeutics.
Co-investorsPappas CapitalPerceptive Xontogeny VentureRock Springs Capital
Axonics Modulation, now part of Boston Scientific, develops medical devices in the field of neuromodulation therapies for patients.
HealthtechMedical Devices
Raymond Cohenin
Co-investorsAPERTURE Venture PartnersGilde Healthcare
Non-surgical, non-pharmacologic devices to induce weight loss
Co-investorsDelos CapitalArboretum VenturesHighland Capital PartnersSante Ventures
Bolt Medical develops the Bolt IVL intravascular lithotripsy system, a laser-based balloon catheter platform that fractures arterial calcium using acoustic pressure waves to treat coronary and peripheral artery disease.
HardwareHealthtechMedical DevicesMarlborough, US
Co-investorsBeyond Next Ventures
cAMPfield is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for immune-mediated inflammatory diseases, primarily inflammatory bowel disease (ulcerative colitis and Crohn's disease).
BiotechHealthtech
Graham Heap(President, Research and Development)inEzequiel Neimark(Head of Clinical Development)inTaylor Spector(Head of Medical Affairs)inScott Stirn(Head of CMC)in
Co-investorsFrazier Life Sciences
Molecular diagnostics company commercializing tools for diagnosing cardiovascular disease.
BiotechRedwood City, US
Mark Monane(Executive Officer)Gwen R. Carscadden(Executive Officer)David L. Levison(Executive Officer, Director)Deborah L. Kilpatrick(Executive Officer)inRobert F. Werner(Executive Officer)Douglas T. Ross(Executive Officer)
Co-investorsPappas Capital
Activating the immune system to recognize and destroy tumor cells.
BiotechCambridge, US
Art Krieg(Executive Officer, Director)Barry Labinger(Executive Officer, Director)Chuck Abdalian(Executive Officer)David Mauro(Executive Officer)Karen Brennan(Executive Officer)Charles Yon(Executive Officer)
Co-investorsDecheng CapitalF-Prime CapitalSofinnova VenturesNovo HoldingsvenBio Partners
BiotechChelsea, US
RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)inMARK IWICKI(Executive Officer, Director)inMARTIN FREED(Executive Officer)in
BoardROB HOPFNER(Director)in
Co-investorsCanaan PartnersSofinnova VenturesBay City CapitalFountain Healthcare PartnersOrbiMedRA Capital
Cohere Health provides a platform aimed at aligning the interests of patients, physicians, and health plans to support care decisions and improve member outcomes.
AI & Machine LearningDigital HealthEnterprise SoftwareHealthtechSaaSBoston, US
Siva Namasivayam(Executive Officer, Director)inRobert Shepardson(Executive Officer)inKristen Carucci(Executive Officer)inDuncan Reese(Executive Officer)
BoardDavid Barrett(Director)Amir Debourou(Director)
Co-investorsCota CapitalFlare Capital PartnersDeerfield Management CompanyDefine VenturesFlare Capital StrategiesPolaris Partners+1 more
Cohere Technologies develops software for mobile and wireless networks, including its Universal Spectrum Multiplier (USM) for 4G and 5G and Pulsone technology based on the Zak-OTFS waveform, aimed at Mobile Network Operators.
AI & Machine LearningCloud ComputingDeep TechDefense TechEnterprise SoftwareHardwareSanta Clara, US
Shlomo Rakib(Executive Officer, Director)in
BoardRon Bernal(Director)inKrishna Kolluri(Director)Chris Schaepe(Director)
Co-investorsLightspeed Venture PartnersNew Enterprise Associates (NEA)Bell VenturesIntel CapitalJuniperKoch Disruptive Technologies+3 more
.jpeg){kind=logo}
Cortica provides in-home, in-clinic, and telehealth neurological therapies for children with autism and developmental differences, integrating neurological, biomedical, behavioral, speech-language, and sensorimotor treatments.
Digital HealthHealthtechMedical DevicesSan Diego, US
Dr. Suzanne Goh(Founder)Neil Hattangadi(Founder)inBriana Elvaiah(Executive Officer)inSuzanne Goh-Hattangadi(Founder)
BoardRyan Drant(Director)inStephen Anastos(Director)
Co-investors.406 VenturesAIFAPERTURE Venture PartnersCVS Health VenturesEcho Health VenturesOptum Ventures+6 more
JAN46 is an online gaming platform offering game top-ups (in-game credits/items) with automated delivery, along with esports tournaments featuring live brackets and streaming, and player community tools.
ConsumerGaming
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLumira VenturesMenlo Ventures+5 more
Eargo was a hearing aid company that provided high-quality hearing aids and related care services.
HealthtechMedical DevicesMountain View, US
Raphael Michel(Founder)Christian Gormsen(Executive Officer, Director)William Brownie(Executive Officer)Peter Tuxen Bisgaard(Director)Daniel Shen(Founder)Florent Michel(Founder)
Co-investorsBirchmere VenturesDolby Family VenturesMaveronNew Enterprise Associates (NEA)Peterson VenturesCrosslink Capital+4 more
Endeavor BioMedicines is a biopharmaceutical company developing medicines aimed at treating patients with serious, intractable diseases, with the goal of altering disease progression rather than only slowing it.
BiotechSan Diego, US
John Hood(Co-Founder, Chief Executive Officer & Executive Chairman)inWing Cheong Lam(Director)Bernard Davitian(Director)Raghu Saripalli(Executive Officer)Monal Mehta(Director)inMiguel de los Rios(Co-Founder & Chief Scientific Officer)in
Co-investorsFidelity InvestmentsOmega Funds
Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes.
Digital HealthHealthtechMedical DevicesMinneapolis, US
Stacey Pugh(Leadership (CEO))inChris Sorli, MD, PhD(Chief Medical Officer)inKrissy Wright(Chief Financial Officer)inLian Cunningham, MD, PhD(VP Clinical Affairs)inMelanie Hess(Regulatory Affairs Leadership)inMatt Cambronne(Technical/Engineering Leadership)in
Co-investorsArboretum VenturesHatteras Venture PartnersIntuitive VenturesLumira VenturesSoutheast Minnesota Capital Fund
Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy.
BiotechMedical DevicesSan Diego, US
Pam Taub(M.D., FACC, Founder)Alan Maisel(M.D., Founder)Francisco Villarreal(M.D., Ph.D., Founder)Jonathan Taub(Co-founder and first Chief Executive Officer)Guillermo Ceballos(M.D., Founding Scientist)Pam Taub, M.D., FACC(Co-founder)
Co-investorsBluebird VenturesBroadview VenturesAdams Street PartnersARCH Venture PartnersVertex VenturesVertex Ventures HC
Biopharma developing HDL-C regulating therapies; listed 2000.
BiotechAnn Arbor, US
Roger S. Newton(Director)inTim M. Mayleben(Executive Officer, Director)
BoardDaniel Janney(Director)Dov A. Goldstein(Director)Nicole Vitullo(Director)inPatrick Enright(Director)in
Co-investorsAisling CapitalAlta PartnersArboretum VenturesARCHIMED JapanAsset Management CompanyCanaan Partners+3 more
FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care.
Digital HealthHardwareMedical DevicesDublin, IE
Co-investorsAndera PartnersGimvIreland Strategic Investment FundLightstone VenturesNew Enterprise Associates (NEA)Seventure Partners+5 more
Generate Life Sciences was a reproductive, newborn stem cell, and genetic services company offering products and services to help families grow and protect their families.
BiotechDigital HealthHealthtech
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.
BiotechHealthtechSouthbury, US
Kevin Russ(Chief Executive Officer)inPeter DiLaura(Chief Executive Officer and Board Director)inWaters Kellogg(Director)Lucas B. Turner(Director)Joshua Dotson(Director)Holger Koehler(Director)
Co-investorsOrbiMedWellington ManagementVersant Ventures
Predictive Oncology (POAI) operates an AI/ML platform powered by a biobank of over 150,000 tumor samples across 137 cancer types to predict tumor-drug response for oncology drug discovery.
AI & Machine LearningBiotechHealthtechPittsburgh, US
GERALD J. VARDZEL JR.(Executive Officer, Director)DOUGLAS ARMSTRONG(Executive Officer, Director)
BoardROBERT D. KEYSER JR.(Director)RICHARD AULICINO(Director)
Infinant Health develops probiotic products based on B. infantis strains that work with breast milk to support the infant gut microbiome, including its INF108 drug strain aimed at preventing necrotizing enterocolitis (NEC) in premature infants.
BiotechDigital HealthFemTechHealthtechMedical DevicesWellness & FitnessSacramento, US
David J. Kyle(Executive Officer, Director)inJ. Bruce German(Co-founder)David Mills(Co-founder)inCarlito Lebrilla(Co-founder)Daniela Barile(Co-founder)Samara Freeman(Co-founder & Director of Intellectual Property and Regulatory Affairs)in
Co-investorsAcre Venture PartnersBow CapitalHorizons VenturesiSelect FundSpruce Capital PartnersXeraya Capital+1 more
BiotechBoston, US
Axel Bolte(Executive Officer, Director)inReinaldo Diaz(Director)Joseph Schlessinger(Executive Officer, Director)
BoardEdward Mathers(Director)Rob Hopfner(Director)inMartin Edwards(Director)
Co-investorsNew Enterprise Associates (NEA)Pivotal Life SciencesSanofi VenturesSofinnova Ventures
IntelyCare operates a healthcare talent marketplace that connects nurses with care settings including hospitals, clinics, and other healthcare facilities.
B2B MarketplacesFuture of WorkHealthtechHR TechQuincy, US
Ike Nnah(Executive Officer, Director)inDavid Coppins(Executive Officer, Director)inPrince Nnah(Director)
Co-investorsEastward Capital PartnersEndeavour VisionEquitage Ventures, L.L.C.First Trust Capital PartnersGenerator VenturesKaiser Permanente Ventures+4 more
Jazz Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases and cancers, with a focus on oncology and biomarker-driven therapies such as those targeting HER2-expressing cancers.
BiotechHealthtech
Co-investorsProspect Venture PartnersRex Health VenturesSolas BioVentures
Jazz provides an AI-powered investigation platform that automatically analyzes suspicious data activities and delivers clear narratives about security incidents.
AI & Machine LearningCybersecurityEnterprise SoftwareSaaS
Ido Livneh(Founder)inNoam Issachar(Founder)inJake Turetsky(Founder)Yonatan Zohar(Founder)
Co-investorsEncoded VenturesGlilot Capital PartnersMassMutual VenturesTeam8Team8 Capital
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersFrazier Life SciencesLongwood FundBiotechnology Value Fund+2 more
Lexeo is a clinical-stage genetic medicine company developing gene therapies that target the genetic causes of cardiovascular diseases.
BiotechDigital HealthHealthtechNew York City, US
Ronald Crystal, MD(Founder & Chief Scientific Adviser)R. Nolan Townsend(Chief Executive Officer)inNarinder Bhalla, MD(Chief Medical Officer)José Manuel Otero, PhD(Chief Operating Officer)Louis Tamayo(Chief Financial Officer)in
Co-investorsOrbiMed
LimFlow develops a medical device system for the treatment of chronic limb-threatening ischemia.
HealthtechMedical Devices
Co-investorsSofinnova Partners
Locus Biosciences develops engineered bacteriophage therapies for treating bacterial infections and conditions in immunology, oncology, and CNS disorders.
AI & Machine LearningBiotechDeep TechHealthtechRaleigh, US
Paul Garofolo(CEO & Co-founder)NICK TAYLOR(Executive Officer)inNick Conley(Vice President of Technology (Co-founder of EpiBiome, acquired by Locus))in
BoardGEOFFREY GLASS(Director)inDAVID JOHNSTON(Director)BARY BAILEY(Director)
Co-investorsArtis VenturesAbstract VenturesHemisphere Ventures LLCDomain AssociatesStarlight VenturesTencent Holdings
Acquired by Shire in 2014 (now part of Takeda).
BiotechMedical Devices
Co-investorsFrazier Life SciencesOberland CapitalPappas CapitalRiverVest Venture PartnersSanofi Ventures
Mobia Medical (formerly MicroTransponder) develops Vivistim Paired VNS Therapy, an FDA-approved vagus nerve stimulation treatment for chronic ischemic stroke survivors with moderate to severe upper extremity impairment.
HealthtechMedical Devices
Jordan Curnes(Co-Founder)in
Co-investorsGreen Park & Golf VenturesOUP (Osage University Partners)US Venture Partners
Focused on Engineered Toxin Bodies immunotoxins for cancer treatment.
BiotechAustin, US
Eric E. Poma(Executive Officer, Director)Jason S. Kim(Executive Officer)David R. Hoffmann(Director)David Hirsch(Director)David Valacer(Executive Officer)Harold Selick(Director)
Co-investorsExcel Venture ManagementSante Health Ventures
Molecular Templates, Inc. was a clinical-stage biopharmaceutical company formerly based in Austin, TX.
BiotechAustin, US
Co-investorsHitecVision Advisory ASSofinnova VenturesSolasta Ventures
Murj provides a software platform for cardiac clinics, tailoring its solution to each clinic's specific workflows and challenges.
Digital HealthHealthtechMedical DevicesSaaSSanta Cruz, US
Patrick Beaulieu(Founder)inTodd Butka(Founder)
BoardMark Bartell(Director)Reed Gaither(Co-founder)
Co-investorsTrue Ventures
BiotechDublin 1
Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)
Co-investorsAisling CapitalEcoR1 CapitalFrazier Life SciencesMESA VERDE VENTURE PARTNERSNovartis Venture Fund
Nalu Medical develops a non-integrated neurostimulation system that uses electrical impulses to interrupt pain signals for patients with intractable chronic nerve pain.
HardwareHealthtechMedical DevicesCarlsbad, US
Earl Fender(President & CEO)inLee Hartley(Executive Officer)inAllen Meacham(Executive Officer)inBick Sellers(Executive Officer)inThomas A. West(Executive Officer, Director)inJeffrey Swiecki(Executive Officer)
Co-investorsAPERTURE Venture PartnersB Capital GroupB4 CapitalDecheng CapitalEndeavour VisionMVM Life Science Partners+3 more
.jpeg){kind=logo}
NOCD provides specialized treatment for obsessive-compulsive disorder through live video sessions with OCD-trained therapists and 24/7 in-app support between sessions, using exposure and response prevention (ERP) therapy.
Digital HealthHealthtechMental HealthChicago, US
LARRY TRUSKY(Executive Officer)inStephen Smith(Cofounder)in
BoardGLEN TULLMAN(Director)in
Co-investors7wire VenturesChicago VenturesCorewell Health VenturesF-Prime CapitalKaiser Permanente VenturesMeridian Street Capital+3 more
NxStage provides home dialysis products and support for people with chronic kidney disease and end-stage renal disease, including home hemodialysis and peritoneal dialysis.
Digital HealthHardwareHealthtechMedical DevicesLawrence, US
Co-investorsCross Creek AdvisorsAdams Street PartnersAtlas VentureLightspeed Venture Partners
On Belay provides tools, resources, and guidance to support primary care teams in transitioning to value-based care models and strengthening their practices across the United States.
Enterprise SoftwareHealthtechSaaS
Co-investors.406 VenturesMaverick Ventures
Douglas Hanahan(Founder)Gideon Bollag(Founder)Joseph Schlessinger(Founder)
Co-investorsMenlo VenturesNorthpond Ventures
Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy.
BiotechHealthtechAptos, US
Jason Levin(Founder, Director and Chief Executive Officer)Robert M. Myers(Executive Officer, Director)
BoardMichael Wasserman(Director)Patrick Enright(Director)inElisha (Terry) Gould(Director)Ernest Mario(Director)
Co-investorsH.I.G. CapitalH.I.G. HealthBridge PartnersAbingworthAdams Street PartnersAgent Capital
This page is a distribution, marketing, and reseller partner directory for PRWeb, an online press release distribution service.
Marketing TechMedia & EntertainmentSaaS
Co-investorsAdvance Venture PartnersAngel Physicians FundAvestria VenturesAviv Venture CapitalBIGR VenturesBlue Venture Funds+15 more
Polares Medical is a medical device company developing a device for treating mitral valve regurgitation.
HealthtechMedical DevicesPalo Alto, US
Alex Khairkhahan(Founder)in
Co-investorsDecheng CapitalEarlybird Venture CapitalEndeavour VisionIDO Investments
Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications.
BiotechHealthtechSan Diego, US
Eric Ostertag(Executive Officer, Director)Mark Gergen(Executive Officer, Director)
BoardAdrian Howd(Director)David Hirsch(Director)
Co-investorsAisling CapitalRapha Capital Management, LLCVivo Capital
Practice Fusion provides a cloud-based electronic health record (EHR) platform with integrated medical billing services and e-prescribing for independent medical practices.
Digital HealthHealthtechSaaSSan Francisco, US
Ryan Howard(Executive Officer, Director)in
BoardMark Goines(Director)Beth Seidenberg(Director)inMichael Harden(Director)Cora Tellez(Director)
Co-investorsBand of AngelsCanvas VenturesArtis VenturesDeerfield Management CompanyFelicis VenturesFounders Fund+6 more
Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.
BiotechDeep TechHealthtechSouth San Francisco, US
Cameron Pitt(Executive Officer, Director)inDerek Metzger(Executive Officer)
BoardMaha Katabi(Director)inPerry Nisen(Executive Officer, Director)inMaria Fardis(Director)inRajul Jain(Director)in
Co-investorsFinchley Healthcare VenturesSofinnova VenturesVida VenturesBiotechnology Value FundFrazier Life Sciences
Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases.
BiotechDigital HealthHealthtechMedical DevicesCharlottesville, US
Francisco Portell(Co-founder & Vice President, Pharmaceutical Development)Allen Cunningham(Co-founder & Chief Operating Officer)inNancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)inShaharyar Khan(Co-founder & Chief Scientific Officer)in
BoardFrancesco De Rubertis(Director)in
Co-investorsMedicxiBain Capital Life SciencesRA Capital
A biopharmaceutical company that discovers, develops, and delivers medicines and vaccines, with research and development across respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Co-investorsCapital Midwest FundFrazier Life SciencesRA CapitalVivo CapitalOxford Finance LLC
Solta Medical develops and sells a portfolio of aesthetic skin treatment devices, including the Thermage line, used by medical and cosmetic practices to address common skin concerns such as skin tightening and contouring.
HardwareMedical DevicesWellness & Fitness
Co-investorsNew Enterprise Associates (NEA)
Somatus provides value-based, integrated kidney care and a congestive heart failure management solution for patients, providers, and health plan partners.
Digital HealthHealthtechMclean, US
Ikenna Okezie(Executive Officer, Director)inAlexander Houlday(Executive Officer)inStacey Queen-Pyndell(Executive Officer)Larry Renfro(Interim President & CEO)
BoardAnna Haghgooie(Director)Anthony Welters(Director)
Co-investorsFlare Capital PartnersOptum VenturesHealthQuest CapitalBlue Venture FundsDefy PartnersRA Capital+7 more
Clinical-stage biotech developing cell therapy products for transplant and autoimmune conditions
BiotechLouisville, US
Suzanne Ildstad(Executive Officer, Director)Scott Requadt(Executive Officer, Director)Geoff Mackay(Director)Francois Nader(Director)
BoardSandip Agarwala(Director)inMark McDade(Director)in
Co-investorsAisling CapitalKeyhorse CapitalQiming Venture Partners USAViking GlobalBlackstone Life SciencesCitadel+3 more
Theseus builds robotic situational awareness software using visual positioning for drones that operate in GPS-denied environments.
Advanced ManufacturingAI & Machine LearningDefense TechHardwareRoboticsSan Francisco, US
Ian Laffey(Founder)inSacha Lévy(Founder)inCarl Schoeller(Founder)
Co-investorsY CombinatorFirst Round CapitalPioneerAntlerEndor CapitalForesite Capital+7 more
BiotechCambridge, US
William C. Shakespeare(Director)in
BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)inCarl Gordon(Director)in
Co-investorsForesite CapitalNextech InvestNexTech VenturesOmega FundsOrbiMedPontifax Venture Capital+2 more
Constellation Pharmaceuticals was a Cambridge, MA clinical-stage biopharmaceutical company developing epigenetics-based cancer therapies, including BET and EZH2 inhibitors.
BiotechHealthtech
Co-investorsClal Biotechnology IndustriesExSight VenturesTachyon VenturesThe Column Group
BiotechCambridge, US
James G. McArthur(Executive Officer)Abraham N. Ceesay(Executive Officer)Christoph M. Adams(Executive Officer, Director)
BoardMette Kirstine Agger(Director)David Mott(Director)Sandip Agarwala(Director)
Co-investorsAlexandriaLundbeckfonden VenturesNew Enterprise Associates (NEA)
Tourmaline Partners is an outsourced trading firm that provides trading execution and operational services to institutional buy-side clients across equities, derivatives, and listed products globally.
Enterprise SoftwareFintechSaaS
Aaron Hantman(Chief Executive Officer, Founder)inDaniel DiSpigna(Chief Operations Officer, Founder)Henry Higdon(Head of Global Equity Trading, Founder)in
Co-investorsCopley Equity Partners LLCTech Coast Angels
Biotechnology company developing cellular therapies for organ transplantation and autoimmune disorders.
Co-investorsAnjostAvoro Capital AdvisorsScion Life SciencesTCG CrossoverVivo CapitalAvoro Ventures+1 more
BiotechSouth San Francisco, US
Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)
BoardSandra Coufal(Director)David Bonita(Director)inKlaus Veitinger(Director)inRobert Alpern(Director)
Co-investorsAvoro Capital AdvisorsWellington ManagementFrazier Life SciencesHercules Capital, Inc.OrbiMed
Biotechnology company developing products for overactive bladder and irritable bowel syndrome.
BiotechMalvern, US
Douglas Gessl(Executive Officer)inJames Walker(Executive Officer, Director)in
BoardScott Morenstein(Director)David Hirsch(Director)James Bennethum(Director)Stephen Tullman(Director)
Co-investorsFountain Healthcare PartnersSamsara BioCapital
BiotechSan Carlos, US
Surag Mantri(Executive Officer, Director)
BoardJustin Klein(Director)inMatthew Sprinkel(Director)Amir Abolfathi(Director)Varun Gupta(Director)in
Co-investorsBoutique Venture PartnersNeotribe VenturesVensana Capital
Viridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit.
BiotechDigital HealthMedical DevicesWaltham, US
Jonathan Violin(Executive Officer, Director)in
BoardPeter Harwin(Director)Tomas Kiselak(Director)
Co-investorsBroadview VenturesMRL Ventures Fund
WelbeHealth operates a Program of All-Inclusive Care for the Elderly (PACE) that provides integrated medical and social services to seniors, including primary care, dental, vision, hearing, in-home care, transportation, and social activities.
Digital HealthHealthtechWellness & FitnessCalifornia, US
Si France, MD(Founder)inCLANCY SI FRANCE(MANAGER AND CHIEF EXECUTIVE OFFICER OF ISSUER)
BoardLIAM DONOHUE(MANAGER OF ISSUER)inADAM GROFF(MANAGER OF ISSUER)inMICHAEL ZUBKOFF(MANAGER OF ISSUER)JONATHAN LIM(MANAGER OF ISSUER)
Co-investors.406 VenturesAlumni VenturesF-Prime CapitalGeneral AtlanticTown Hall Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Alphaeon89BioAimmuneAllergen ResearchAmphora MedicalAqueSysCadenceCadence PharmaceuticalscAMPfieldcAMPfield TherapeuticsCardero TherapeuticsCivitasCohereCollegiumCorceptCydanCydan DevelopmentCydan IIDascenaEncore DermatologyEsperionGcs WebInfaCareInfacare PharmaceuticalInflazomeKaNDyKaNDy TherapeuticsKestra Medical TechnologyLexeo TherapeuticsNeuranaNeurana PharmaceuticalsNxStageOn BelayOrbusPixelOpticsPoseidaPrecision DermatologyPrecision TherapeuticsRapidmicrobioRenewSoltaSublimity TherapeuticsSymparaTwelveVelomedixVera TherapeuticsXanodyneXeris Biopharma
Exits · 31
20 IPOs · 11 acquisitions · showing 28VeradermicsNYSE: MANECeribellNASDAQ: CBLLAEON BiopharmaNYSE: AEONBioAge LabsNASDAQ: BIOABoston ScientificNYSE: BSXCG OncologyNASDAQ: CGONCollegium PharmaceuticalNASDAQ: COLLCorcept TherapeuticsNASDAQ: CORTCytomX TherapeuticsNASDAQ: CTMXKALA BIONASDAQ: KALAKestra Medical TechnologiesNASDAQ: KMTSMicroTransponderNASDAQ: MOBIMirum PharmaceuticalsNASDAQ: MIRMPROCEPT BioRobotics CorpNASDAQ: PRCTRapid Micro BiosystemsNASDAQ: RPIDRxsightNASDAQ: RXSTSUTROVAX, INC.NASDAQ: PCVXVaxcyteNASDAQ: PCVXVeratxNASDAQ: VERAZenas BiopharmaNASDAQ: ZBIO89bio (NASDAQ: ETNB)acq. by RocheAmphora Medicalacq. by HologicAptus Endosystemsacq. by MedtronicHelomicsacq. by Predictive OncologyLumena Pharmaceuticalsacq. by ShireNxStage Medicalacq. by Fresenius Medical CarePentec Health Celebrates 35th Anniversaryacq. by Wellspring Capital ManagementThumbnail for Constellation Pharmaceuticalsacq. by MorphoSys
Portfolio news
latest coverage across their companiesEsperion Therapeutics · stocktitan.net · Jun 8, 2026
Endogenex · endogenex.com · Mar 26, 2026
Nalu · trysignalbase.com · Mar 25, 2026
Ventaris Surgical · finsmes.com · Jan 12, 2026
Theseus · techcrunch.com · Apr 17, 2025
Fund performance · per public LP disclosures
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Longitude Venture Partners IIILPs: Los Angeles City Employees' Retirement System, Maryland State Retirement and Pension System | 2016 | — | 16.8% | 1.68x | 0.96x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings · 7
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Veradermics | 11.3% | $100.00 | Apr 2026 | $465.4M |
| CG Oncology | 6.2% | $28.00 | Dec 2024 | $130.5M |
| Veratx | 11.9% | $15.00 | Feb 2022 | $46.4M |
| Ceribell | 7.3% | $17.00 | Oct 2024 | $42.1M |
| Zenas Biopharma | 5.2% | $17.00 | Sep 2024 | $35.1M |
| KALA BIO | 8.8% | $15.00 | Jul 2017 | $30.8M |
| BioAge Labs | 3.8% | $18.00 | Sep 2024 | $23.6M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘ2 insider ownership filings (Forms 3/4/5)
at Veradermics, Inc (MANE)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Longitude Capital made?
- Longitude Capital has 152 tracked investments, 31 of which have exited, including 6 dated in the last 24 months.
- What stage does Longitude Capital invest at?
- Longitude Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.
- What is Longitude Capital's typical check size?
- Longitude Capital typically writes checks of $10M – $30M.
- What sectors does Longitude Capital focus on?
- Longitude Capital focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Longitude Capital located?
- Longitude Capital is headquartered in Menlo Park, US.
- Does Longitude Capital lead rounds?
- Yes, Longitude Capital leads investment rounds.
- Who does Longitude Capital co-invest with?
- Longitude Capital most often shares deals with Frazier Life Sciences, RA Capital, New Enterprise Associates (NEA), among 211 tracked co-investors.
Co-investors · 6
Pivotal Life Sciences is a global healthcare investment firm backing companies developing high-impact therapeutics for major unmet medical needs, operating across venture capital, venture building, and public equity strategies.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Bain Capital is a global private investment firm operating across private equity, growth and venture, credit, real assets, and capital solutions, partnering with companies to create value across sectors and regions.
Vensana Capital is a venture capital and growth equity investment firm focused on partnering with entrepreneurs building breakthrough medical technology innovations to transform healthcare.
Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.
Firms observed investing alongside Longitude Capital, from public investor directories. Shared companies are the overlap with Longitude Capital's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
EQT Life Sciences (formerly LSP) is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally.
ARTIS Ventures is a venture capital firm investing in breakthrough companies at the convergence of technology and biology, with a focus on healthcare and life sciences ('TechBio'). It backs founders across biotech, therapeutics, digital health, and frontier technologies.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.